INTRODUCTION {#S1}
============

Parkin and PINK1 promote the removal of dysfunctional mitochondria, a process termed mitophagy, by specifically targeting damaged mitochondria for lysosomal degradation ([@R36]). Loss-of-function mutations and deletions in PINK1 and Parkin have been associated with multiple forms of cancer, indicating that both proteins are possible tumor suppressors. Pathogenic PINK1 germline variants predispose individuals to high-risk neuroblastomas ([@R43]). *PARK2*, the gene that encodes Parkin, resides within a common fragile site at chromosome 6q26 ([@R29]). Parkin mutations and deletions have also been identified in sporadic colorectal cancer, glioblastomas, and other cancer types ([@R42]; [@R53]). Previous literature has proposed mechanisms by which PINK1 and Parkin independently influence the cell cycle, but these studies did not consider mitophagy ([@R5]). PINK1's known roles include activation of inactive cytosolic Parkin upon mitochondrial damage, while in the absence of mitochondrial damage, PINK1 is constitutively degraded and thus unable to be contribute to cellular processes occurring in the absence of mitochondrial damage ([@R36]). Therefore, we hypothesized that both PINK1- and Parkin-mediated mitophagy must influence cell cycle progression, albeit directly or indirectly.

During mitophagy, PINK1 and Parkin trigger the translocation and activation of Tank Binding Kinase 1 (TBK1) to damaged mitochondria ([@R15]; [@R23]; [@R30]; [@R45]). TBK1 phosphorylates autophagy receptors at the mitochondria to promote binding between the developing autophagosome and damaged mitochondria ([@R15]; [@R23]; [@R30]; [@R45]). Our data demonstrate that TBK1 acts at both the damaged mitochondria during mitophagy and at centrosomes, where it is activated and necessary during mitosis. We show that both PINK1 and Parkin genetically interact with tumor-suppressing genes and uncover that PINK1/Parkin-mediated activation of TBK1 causes its sequestration at damaged mitochondria, thus blocking TBK1's ability to participate in cell cycle progression.

RESULTS {#S2}
=======

PINK1 and Parkin Genetically Interact with DNA Damage Cell Cycle Checkpoint Proteins {#S3}
------------------------------------------------------------------------------------

Ataxia telangiectasia mutated (ATM) is a serine threonine kinase activated in response to DNA damage, hypoxia, and oxidative stress that results in the phosphorylation of hundreds of targets involved in cell-cycle arrest, DNA repair, and apoptosis and senescence ([@R26]). Several reports also support the notion that loss of ATM leads to mitochondrial dysfunction ([@R10]; [@R48]; [@R51]). This observation led us to hypothesize that ATM and Parkin may function together in regulating mitochondrial responses to stress. To further explore this possibility, we undertook a genetic approach crossing ATM-knockout (KO) and Parkin-KO mice to investigate the effect of loss of ATM on Parkin-mediated phenotypes.

Parkin-KO mice are viable, with no overt phenotypes, neuro-degeneration, or reduced lifespan ([@R11]). ATM-KO mice are also born viable, but half of the mice develop thymic lymphomas after 3 months of age ([@R3]). Because both of these genetic mutant murine lines are healthy at birth, it was unanticipated that mice with a combinatory loss of ATM and Parkin were found at sub-Mendelian ratios, indicating a synthetic lethality ([Table 1](#T1){ref-type="table"}; [Figure S1](#SD1){ref-type="supplementary-material"}). In order to more readily explore genetic interactions of the ATM and Parkin pathways, we confirmed this finding in *Drosophila*.

We crossed the *park*^*25*^ mutant fly with a combination of ATM mutant fly lines harboring various point mutations ([Table 2](#T2){ref-type="table"}). Flies homozygous for the STOP codon mutations (ATM3/ATM3 and ATM6/ATM6) are lethal ([@R35]). Hence, we made combinatory fly lines to disrupt ATM. As in the mouse, these crosses resulted in a synthetic lethality, resulting in fewer double-mutant pupae hatching when both alleles were mutated ([Table 2](#T2){ref-type="table"}). PINK1 and Parkin reside in the same pathway to control mitophagy and were also shown with epistasis experiments in *Drosophila* ([@R7]; [@R34]; [@R41]). This interaction with ATM extended to PINK1 as heteroallelic combinations of *Pink1*^*B9*^ ATM flies also eclosed below the expected number of progeny ([Table 2](#T2){ref-type="table"}).

The Loss of ATM Does Not Affect PINK1 Accumulation or Parkin Translocation upon Mitochondrial Damage {#S4}
----------------------------------------------------------------------------------------------------

The HCT116 cell line expresses endogenous ATM and Parkin, maintains an intact p53 response, and has been extensively used to study Parkin-mediated mitophagy ([@R47]; [@R55]). To test whether ATM and PINK1/Parkin were directly interacting, we generated ATM-KO HCT116 cells using CRISPR ([Table S1](#SD1){ref-type="supplementary-material"}). Using this cell line, we probed the effects of ATM loss on PINK1/Parkin in the context of mitochondrial dysfunction.

Mitochondrial damage induced by an antimycin A and oligomycin A cocktail (OA) caused Parkin translocation and PINK1 accumulation as expected ([@R23]) and was completely ATM independent ([Figures S2A](#SD1){ref-type="supplementary-material"}--[S2C](#SD1){ref-type="supplementary-material"}). Mitochondrial damage did not induce autophosphorylation and activation of ATM ([Figure S2C](#SD1){ref-type="supplementary-material"}). These results were confirmed in healthy human and ATM patient fibroblast lines ([Figure S2D](#SD1){ref-type="supplementary-material"}). In conclusion, Parkin-mediated mitophagy was uninhibited in the absence of ATM, and the loss of ATM was not sufficient to trigger Parkin translocation without exogenous mitochondrial damage.

Given that ATM had no role upstream of Parkin, we examined events downstream of PINK1 accumulation and Parkin translocation. In cells stably expressing tagged Parkin, prolonged treatment with OA showed that the presence or absence of ATM had no effect on the degradation of Mfn2, a Parkin substrate ([@R47]) ([Figure S2E](#SD1){ref-type="supplementary-material"}). The accumulation of p62, an autophagy receptor protein, and the lipidation of the autophagosomal protein LC3 occurred with OA treatment, indicating normal progression of mitophagy in the absence of ATM ([Figure S2F](#SD1){ref-type="supplementary-material"}). The loss of inner membrane mitochondrial proteins (COXII and Tim23) and absence of GRP75, a mitochondrial matrix protein, suggested completion of mitophagy in both cell lines with prolonged OA treatment ([Figure S2G](#SD1){ref-type="supplementary-material"}); thus, loss of ATM did not influence Parkin-mediated mitophagy.

We then tested whether the loss of PINK1 or Parkin affected nuclear DNA damage signaling. We confirmed using western blot that our ATM-KO HCT116 cells displayed a typical response to etoposide ([Figure S3A](#SD1){ref-type="supplementary-material"}). We generated Parkin-KO and PINK1-KO HCT116 ([Table S1](#SD1){ref-type="supplementary-material"}; [Figures S3B](#SD1){ref-type="supplementary-material"} and [S3C](#SD1){ref-type="supplementary-material"}) to compare genotypes. We used a homologous recombination (HR) reporter construct (DR-GFP) and a non-homologous end- joining (NHEJ) reporter construct (EJGFP) to test whether DNA damage repair was inhibited when the PINK1-Parkin pathway was disrupted ([Figure S3D](#SD1){ref-type="supplementary-material"}). In brief, DR-GFP or EJGFP cannot express GFP fluorescence unless an *Sce*I restriction site is recombined through HR or NHEJ ([@R4]; [@R37]) ([Figure S3D](#SD1){ref-type="supplementary-material"}). We found that PINK1 and Parkin did not have an impact on HR ([Figure S3E](#SD1){ref-type="supplementary-material"}). The loss of ATM in wild-type cells resulted in deficient HR ([@R20]), which we used as a positive control ([Figure S3E](#SD1){ref-type="supplementary-material"}). We also checked NHEJ, which occurs at a higher rate than HR ([@R25]). Interestingly, we found that NHEJ did appear slightly impaired in PINK1-KO compared with wild-type (WT) and Parkin-KO cells, but not to the extent seen in ATM-KO cells ([Figure S3F](#SD1){ref-type="supplementary-material"}). This did not appear to be dependent on ATM signaling or p53 accumulation ([Figure S3G](#SD1){ref-type="supplementary-material"}).

To determine the specificity of the genetic interaction between ATM and PINK1 and Parkin, we crossed ATR mutant flies with Parkin mutant flies. ATR is a PI3K in the same family as ATM that responds to single-strand breaks by phosphorylating multiple protein targets involved in overlapping pathways with those triggered by ATM activation ([Figure 1A](#F1){ref-type="fig"}) ([@R26]). Unlike ATM, ATR has not been associated in the literature with mitochondrial dysfunction. Interestingly, ATR and Parkin double mutants also caused a synthetic lethality ([Table 2](#T2){ref-type="table"}). Mitochondrial-localized PINK1 and Parkin are unlikely to directly interact with nuclear ATM and ATR. Furthermore, we did not observe robust evidence that PINK1 and Parkin indirectly affected ATM or vice versa ([Figures S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}); therefore, we felt that PINK1/Parkin were most likely influencing a common pathway downstream of ATM/ATR.

CDK1, CDK2, and CDC25 Interact with and Rescue PINK1 and Parkin Thorax Indentations {#S5}
-----------------------------------------------------------------------------------

We screened 14 RNAi fly lines targeted to genes functioning downstream of ATM and ATR to test whether PINK1/Parkin interacted with cell cycle regulation ([Table S2](#SD1){ref-type="supplementary-material"}; [Figure 1A](#F1){ref-type="fig"}). *park*^*25*^ mutant flies display flight muscle degeneration, causing thorax indentations and dopaminergic neuron loss perfectly phenocopying mutant *Pink1*^*B9*^ flies ([@R7]; [@R34]; [@R57]). We scored flies both for survival and for thoracic indentations to identify any genetic interactions with the PINK1/Parkin pathway.

The RNAi fly strain targeting String (*stg*), the CDC25 human ortholog, partially rescued the PINK1 mutant fly thorax indentation phenotype ([Figure 1B](#F1){ref-type="fig"}). CDC25 removes phosphate residues on active sites of cyclin-dependent kinase (CDK) complexes responsible for cell cycle progression ([@R24]). CDK1 and CDK2 are major kinases that drive the cell cycle by binding to cyclin proteins that flux during G1/S and G2/M transitions ([@R24]). In a Parkin mutant background, overexpression of *stg* or a non-degradable *stg* mutant allele (*HA*-*stg*^mKEN.md^) resulted in lethality ([Table 2](#T2){ref-type="table"}).

Further validating the connection to the cell cycle, our screen also identified CDK1 and CDK2 as genetic interactors of both PINK1 and Parkin. Knockdown (KD) of CDK1 and CDK2 using multiple different RNAi fly lines ameliorated both PINK1 and Parkin mutant thorax phenotypes ([Figures 1C](#F1){ref-type="fig"}--[1H](#F1){ref-type="fig"}; [Tables S2](#SD1){ref-type="supplementary-material"} and [S3](#SD1){ref-type="supplementary-material"}). These data support the notion of a genetic interaction between components of the cell cycle machinery and the PINK1/Parkin pathway.

The Loss of Endogenous PINK1/Parkin Interferes with Cell Growth {#S6}
---------------------------------------------------------------

We further explored the effect of PINK1 and Parkin on cell growth by examining primary cell lines lacking PINK1 or Parkin. Using Parkin-KO mouse embryonic fibroblasts (MEFs), we measured cell growth. In comparison with control MEFs, we found that proliferation was accelerated in Parkin-KO MEF lines ([Figure 2A](#F2){ref-type="fig"}) consistent with an increase in the number of Parkin-KO cells at S and M phases ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). Additionally, we examined a PINK1 mutant human fibroblast line and found a trend toward accelerated growth compared with healthy control fibroblast lines, which also exhibited a similar increase in cells entering S and M phases of the cell cycle ([Figures 2D](#F2){ref-type="fig"}--[2F](#F2){ref-type="fig"}). Our data are consistent with other observations reporting that cell division was increased after the loss of PINK1 and Parkin ([@R1]; [@R12]; [@R44]).

TBK1 Is Activated During and Necessary for Mitosis {#S7}
--------------------------------------------------

TBK1's role in innate immunity is extensively studied because it is required to stimulate the interferon response ([@R8]). Our work and that of others previously revealed that TBK1 activation at damaged mitochondria promoted efficient mitophagy dependent on PINK1 and Parkin activity ([@R15]; [@R23]; [@R30]; [@R45]) ([Figure S4](#SD1){ref-type="supplementary-material"}). However, an additional role for TBK1 in mitosis has also been described ([@R32]; [@R38]). Because it represents a potential link between both Parkin-mediated mitophagy and the cell cycle, we tested whether TBK1 was active and necessary for mitosis.

We found that TBK1 was phosphorylated and active during all stages of mitosis at the centrosome and midbody ([Figure 3A](#F3){ref-type="fig"}). This activation was not apparent by western blotting in an asynchronous population, but upon synchronization of cells at G2/M phase, p-TBK1 levels were strikingly increased ([Figures 3B](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}), leading to the question of whether TBK1 was necessary for the G2/M transition. Either pharmacologically inhibiting TBK1 kinase activity or genetic KO of TBK1 ([Table S1](#SD1){ref-type="supplementary-material"}) resulted in a growth defect ([Figures 3D](#F3){ref-type="fig"}--[3F](#F3){ref-type="fig"}); moreover, we observed decreased numbers of cells in M phase in an asynchronous population ([Figure 3G](#F3){ref-type="fig"}). Upon rescue of the TBK1-KO line, we were able to revert the growth phenotype ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). There was an increased presence of polyploidy and multinucleate cells, presumably harboring cytokinetic defects, in the TBK1-KO cells ([Figure 3J](#F3){ref-type="fig"}).

Activated TBK1 Is Sequestered from the Centrosomes to Damaged Mitochondria during Parkin-Mediated Mitophagy {#S8}
-----------------------------------------------------------------------------------------------------------

These data suggest that TBK1 plays an important physiological role in promoting cell cycle progression, and because of TBK1's additional role in promoting mitophagy at damaged mitochondria, we hypothesized that during mitochondrial damage, active TBK1 was sequestered from centrosomes to mitochondria, resulting in cell-cycle arrest. TBK1's interaction with PINK1/Parkin is not direct; however, TBK1 translocation to damaged mitochondria and activation is dependent upon the activation of PINK1 and Parkin ([@R23]). In cells either expressing or lacking Parkin, we synchronized at G1/S followed by release into either normal growth media or OA ([Figure 4A](#F4){ref-type="fig"}). By 9 h post-release in normal growth media, cells progressed through G2/M regardless of the presence or absence of Parkin ([Figures 4B](#F4){ref-type="fig"}, [4D](#F4){ref-type="fig"}, [4E](#F4){ref-type="fig"}). However, in the context of mitochondrial damage, the presence of Parkin inhibited the progression of cells entering the G2/M transition ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}) via sequestration of active p-TBK1 from the centrosome to damaged mitochondria ([Figures 4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Our data suggest that this sequestration blocked the ability of cells to enter mitosis because the status of PINK1 and Parkin had no effect during normal G2/M progression in the absence of mitochondrial damage ([Figure 4E](#F4){ref-type="fig"}).

Mitochondrial damage did negatively affect cell growth ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}) ([@R28]), so to further test the idea that TBK1 sequestration at mitochondria causes decreased mitosis, we attempted two approaches. First, we generated cell lines stably expressing HA-FLAG-tagged and untagged TBK1 as well as YFP-Parkin ([Figure S5A](#SD1){ref-type="supplementary-material"}), hypothesizing that this may allow us to test our model by increasing additional TBK1 availability during mitochondrial dysfunction. However, we found that overexpression of either tagged or untagged TBK1 in a background with endogenous TBK1 caused abnormal activation and localization in the absence of stimuli ([Figures S5B](#SD1){ref-type="supplementary-material"} and [S5C](#SD1){ref-type="supplementary-material"}). We next attempted to physically tether TBK1 to mitochondria using the rapalog-induced dimerization system (FRB-FKBP). We stably expressed FRB-BFP-Fis1 in the TBK1-KO cell line and transfected in FKBP-GFP-TBK1 ([Figure 4F](#F4){ref-type="fig"}). In the absence of rapalog, low levels of FKBP-GFP-TBK1 were predominately cytosolic ([Figure S5D](#SD1){ref-type="supplementary-material"}). However, in the presence of rapalog, FKBP-GFP-TBK1 translocated to mitochondria and colocalized with the membrane potential-dependent dye MitoTracker Red CMXROS ([Figure 4G](#F4){ref-type="fig"}). By physically tethering TBK1 to mitochondria and bypassing exogenous mitochondrial damage, we observed a significant decrease in the number of mitotic cells in asynchronous conditions compared with FKBP-GFP-TBK1-transfected cells without rapalog ([Figure 4H](#F4){ref-type="fig"}).

*Drosophila* Ortholog ik2 Genetically Interacts with PINK1 and Parkin {#S9}
---------------------------------------------------------------------

In a genome-wide screen for kinases that regulate cell cycle, the TBK1 ortholog in flies (ik2) was discovered to regulate mitosis, and KD of ik2 was found to halt cell cycle progression during mitosis, resulting in cytokinetic defects ([@R6]). We decided to test whether ik2 interacted with PINK1 and Parkin genetically. Loss of ik2 on both alleles causes first instar lethality ([@R49]). Unexpectedly, we found that loss of Parkin suppressed the ik2 recessive lethality ([Table 2](#T2){ref-type="table"}). Upon further examination, we found the loss of ik2 caused a reversal of the thorax indentation phenotype in the Parkin and PINK1 mutant flies ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). These experiments provided additional genetic evidence of PINK1 and Parkin's interaction with TBK1.

DISCUSSION {#S10}
==========

Our work demonstrates a strong genetic interaction between tumor-suppressing genes in both mouse and fly and genes involved in mitophagy, leading us to conclude that the PINK1/Parkin pathway influences the cell cycle. We attribute the ability of PINK1/Parkin-dependent mitophagy to cause the translocation and sequestration of active TBK1 at damaged mitochondria to this genetic interaction. This sequestration of active TBK1 at the mitochondria from its physiological role at the centrosome during mitosis contributes to an arrest in G2/M.

TBK1 has previously been suggested to have tumor-suppressing activities and involvement in cell cycle control. It was first identified in a small interfering RNA (siRNA) screen looking for genes causing synthetic lethality with oncogenic K-Ras mutations ([@R2]). Follow up studies reported a more general role for TBK1 in cell cycle, demonstrating its activation during mitosis ([@R32]; [@R38]). Our data agree with these studies, but it is yet unclear how TBK1 is activated at the centrosome and midbody; previous reports disagree as to the targets that TBK1 phosphorylates ([@R22]; [@R38]). Our data showing abnormal TBK1 activation upon overexpression indicate that TBK1 levels and cellular distribution are tightly regulated during each of its physiological roles: mitosis, innate immunity, and selective autophagy. Additional studies are needed to understand TBK1 regulation during mitosis and how it translocates and is selectively activated at different organelles, a topic currently under investigation. [@R32] reported mitotic arrest in the context of Zika infection and attributed the mechanism to the sequestration of active TBK1 at Zika viral particles. These results are consistent with what we observed during mitophagy. Another intriguing line of future inquiry will be to understand how innate immunity ([@R54]) has the potential to suppress tumorigenesis in the context of TBK1.

Mitochondrial damage triggers the activation of p-TBK1 at mitochondria in a PINK1/Parkin-dependent manner ([@R15]; [@R23]; [@R30]; [@R45]), and our data suggest that this response arrests the cell cycle. Mitosis and mitophagy are both tightly regulated processes. Mitosis is a highly bioenergetically demanding process that requires stringent regulation of mitochondrial import, morphology, and distribution during cell cycle progression ([@R14]; [@R18]; [@R19]). Our data indicate that cell cycle progression is arrested during mitophagy. If PINK1 and Parkin are absent, the cell cycle continues to progress. We speculate that progression through mitosis before or without removing damaged mitochondria would be detrimental to the daughter cell. Previous observations found that "fit" healthy mitochondria segregate during cell division in stem cells and yeast daughter cells through an undefined mechanism ([@R16]; [@R21]). We propose that during mitophagy and the clearance of these damaged organelles, it is bioenergetically unfavorable to initiate mitosis. A block in mitosis could be a protective mechanism to halt cellular division during active mitochondrial clearance.

Our data do not support a direct interaction between ATM and Parkin-mediated mitophagy. However, we did find that PINK1-KO cells had impaired NHEJ, and it is possible that Parkin may have a link to other DNA damage repair pathways ([@R50]). [@R50] found that Fanconi anemia complementation group proteins had a distinct role, separate from their function in the DNA damage response, which was required for efficient mitophagy and interacted directly with Parkin. Parkin-null mice have also been found to have increased rates of cancer and tumorigenesis after irradiation or when crossed to a mouse model of colon cancer ([@R42]; [@R58]). Our findings demonstrate that the DNA damage proteins, ATM and ATR, genetically interact with the PINK1/Parkin pathway through their shared function in influencing the cell cycle. This does not exclude other possible types of interactions with other damage-sensing proteins. There may also be overlap between nuclear and mitochondrial stress signaling. Previously, we reported that mtDNA double-strand break signaling may rely partly on nuclear DNA damage pathways for premature senescence ([@R40]).

Chk1 and Chk2 did not revert the *Pink1*^*B9*^ thoracic indentations upon KD ([Table S2](#SD1){ref-type="supplementary-material"}). Unlike CDC25 and the CDKs, Chk1 and Chk2 mutant *Drosophila* do not show dysregulation of cell cycle without the presence of DNA-damaging stimuli ([@R27]; [@R46]). We speculate that this may be why there was no genetic interaction between Chk1/2 and PINK1.

Our genetic data indicate that PINK1 and Parkin interact with the cell cycle by directly interacting with genes influencing cell cycle progression (CDKs and CDC25/*stg*) or with genes that influence the cell cycle but may have additional roles (ATM and TBK1/ik2). The thorax and flight wing develop from adult muscle precursors and a highly proliferative stem cell pool ([@R13]). We evaluated the flies immediately after eclosion, so we did not evaluate a degenerative phenotype upon aging of the post-mitotic thorax muscles but rather a developmental defect that was rescued by the KD of the CDKs required for cell cycle progression ([@R39]). The mouse line is a complete KO of ATM and Parkin, while the *Drosophila* crosses were performed with point mutation mutant lines. ATM-KO mice have less severe phenotypes compared with kinase-dead ATM point-mutant mice, which are embryonic lethal, accounting for possible compensatory mechanisms in null versus kinase-dead mice ([@R9]). Therefore, when evaluating the genetic data, we cannot directly compare findings from mouse and *Drosophila*, only the general outcome. In the *Drosophila* model, some ATM/Parkin and ATM/PINK1 double-mutant flies survived eclosion and notably exhibited phenotypes of each individual mutant fly, indicating that ATM and PINK1/Parkin are likely not in the same pathway, further implying that the genetic interaction is in parallel ultimately converging upon a common function or outcome involved in cell cycle progression. Experiments performed to check for the presence of an interaction between ATM and mitophagy or mitophagy and DNA damage confirm this.

Our report and other evidence suggest a global response to PINK1/Parkin-mediated mitochondrial clearance. Numerous recent efforts have helped elucidate many of the molecular events that occur at the mitochondria as they pertain to Parkin-dependent mitophagy ([@R56]). However, it is becoming apparent that myriad factors contribute to a global cellular response to mitochondrial damage. In a PINK1/Parkin-dependent manner, mitophagy triggers the nuclear translocation of the transcriptional co-activator TFEB, which upregulates genes required for lysosomal biogenesis ([@R31]). The *C. elegans* protein SKN-1 and its human ortholog NRF2, which are transcriptional co-activators involved in mitochondrial biogenesis, are also activated during mitophagy ([@R33]). These data support a global cellular response aimed at arresting cell cycle during mitochondrial quality control.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Alicia M. Pickrell, Ph.D. (<alicia.pickrell@vt.edu>).

The pHAGE untagged TBK1 and pHAGE N-FLAG-HA TBK1 constructs generated in this study have been deposited to Addgene under Cat\# 131791 and 131792, respectively (see [Key Resource Table](#T3){ref-type="table"}). All KO cell lines generated in this study are available by contacting the Lead Contact. All *Drosophila* lines can be obtained from the Indiana University Bloomington *Drosophila* Stock Center, except for the *park*^*25*^ null and the *Pink1*^*B9*^ null flies, which were a kind gift from Dr. Leo Pallanck (University of Washington). CRISPR plasmids were generated with targeting sequences from either published sources or advice from colleagues and are available upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Mice {#S14}

ATM KO mice (ATM^tm1Awb/J^) were crossed with Parkin KO mice (Park2^tm1Shn/J^) (strains from Jackson Laboratories). The nuclear background was C57BL/6J (backcrossed at least \> F10). ATM+/− mice of mixed sexes were bred until 1 year of age. ATM+/− Parkin+/− or ATM+/− Parkin KO mice of mixed sexes were bred until 1 year of age. Parkin KO MEFs were generated with Parkin KO mice of mixed sexes bred until 1 year of age. Genotyping was performed according to Jackson Laboratories. All mouse procedures were performed according to a protocol approved by the NIH/NINDS Institutional Animal Care and Use Committee. Mice were housed in a virus-antigen-free facility at the NIH Division of Veterinary Resources in a 12 hr light/dark cycle at RT and fed *ad libitum* with standard rodent diet.

### Drosophila {#S15}

*Drosophila* strains were maintained on standard cornmeal/molasses medium at 25°C with a 12-hr light-dark cycle. The *park*^*25*^ null and the *Pink1*^*B9*^ null flies were a kind gift from Dr. Leo Pallanck (University of Washington). Fly stocks were obtained from Bloomington Fly Stock Depository ([Table S2](#SD1){ref-type="supplementary-material"}). Multiple male and virgin female flies were set up for experimental crosses. Flies of both sexes were analyzed for phenotype and eclosion except for *PINK1*^*B9*^ crosses where males were examined. Fly survival and phenotyping for thorax indentation were scored 24 hr after eclosion.

### Cell Lines {#S16}

HCT116 cell lines were maintained in McCoy's 5A (Modified) Media with 10% FBS. HEK293T and HeLa cell lines were maintained in DMEM high glucose with 10% FBS, 2mM L-Glutamine, 10mM HEPES, 0.1mM non-essential amino acids, and 1mM sodium pyruvate. Cells were routinely tested for mycoplasma contamination. CRISPR KO lines generated are found in ([Table S1](#SD1){ref-type="supplementary-material"}). The PINK1 KO HeLa cell line was a kind gift from RJY.

### Primary Cells {#S17}

Patient fibroblast lines obtained from the NINDS depository: ND40066, ND36091, ND34769 and from Coriell Institute for Medical Research were as followed: GM05294 and GM02052. Patient fibroblasts and MEF cells were maintained in DMEM high glucose with 10% FBS, 2mM L-Glutamine, 10mM HEPES, 0.1mM non-essential amino acids, and 1mM sodium pyruvate. Cells were routinely tested for mycoplasma contamination. Cells for growth curve experiments were used at matching passage numbers. Pharmacological drugs used in to treat either cell lines or primary cells are as follows: 10 μg/ml oligomycin (EMD Millipore) and 5 μg/ml antimycin A (Sigma), 10 μM etoposide, 1μM BX-795, 100ng/mL nocodazole, 2.5mM thymidine (Sigma), 0.5nM A/C heterodimer (rapalog) (Takara), and 10 μM QVD-OPh (Abcam).

METHOD DETAILS {#S18}
--------------

### MEF Generation {#S19}

Timed pregnant females E12.5--14.5 were sacrificed. Embryos were dissected to remove the cerebrum, internal organs, and limbs. The remaining tissue was digested with 0.5% trypsin-EDTA. MEFs were used between passages 2--4. Each embryo = clone.

### Western Blotting {#S20}

Cells were lysed using 2x LDS buffer containing 50mM DTT and boiled for 15 min. Approximately 50 μg of protein lysate was loaded onto 4%--12% Bis-Tris gels. Proteins were transferred onto PVDF membranes and blocked with 5% non-fat powdered milk. Primary antibodies were incubated 4°C overnight. Antibodies used: PINK1, p-ATM S1981, LC3B, TBK1, p-TBK1 S172, p-Histone H3 S10 and p-Histone H3 T11 (Cell Signaling), pATM S1981, COXII (Abcam), ATM (Cell Signaling or Sigma), Tim23 (BD Biosciences), Mfn2 (in-house), TOM20, Parkin, p53 (Santa Cruz), GAPDH and actin (Sigma), p62 (Cedarlane), and HA.11 (Covance). Secondary HRP-linked antibodies (GE Healthcare) were incubated at RT for 1 hr. Blots were exposed using peroxidase-based ECL (Pierce) detected by a ChemiDoc Imaging System (BioRad).

### CRISPR and Knockout Cell Line Generation {#S21}

CRISPR design was aided by publicly available software provided by MIT [www.crispr.mit.edu](http://www.crispr.mit.edu/). CRISPR sequences are found in [Table S1](#SD1){ref-type="supplementary-material"}. Primers were annealed and cloned into the linearized gRNA vector, which was a gift from George Church (Addgene \#41824) using the Gibson Assembly Cloning Kit (NEB). HCT116 or HeLa cells were cotransfected using Lipofectamine LTX (Invitrogen) or X-trem-eGENE9 (Roche) using the above CRISPR plasmid, pEYFP-C1 (Clonetech), and the hCas9 plasmid, which was a gift from George Church (Addgene \#41815) or was cloned into SpCas9--2A-Puro, which was a gift from Feng Zhang (Addgene \#48139). YFP-positive cells were FACS sorted or selected with 1 μg/mL puromycin and serially diluted for single colony clones. DNA was extracted using the Zymo gDNA Isolation Kit and genotyped using primers ([Table S1](#SD1){ref-type="supplementary-material"}). PCR products were cloned using CloneJET PCR cloning kit (Invitrogen) according to the manufacturer's instructions. Clones were sequenced to verify KOs ([Table S1](#SD1){ref-type="supplementary-material"}).

### Synchronizing Cells {#S22}

To synchronize cells at the G1/S transition, cells were subjected to a double thymidine block (DTB). In brief, cells were exposed to thymidine-containing media for 17 hr, released in fresh media for 8 hr, and returned to thymidine-containing media for another 16 hr. Cells synchronized at G2/M phase were treated for 16 hr with 100ng/mL of nocodazole.

### Cloning {#S23}

pBMN-mCherry-Parkin and pBMN-YFP-Parkin were cloned into *BamH*I--SalI sites of the pBMN-Z vector to generate stable cells lines as previously described ([@R55]) (Addgene \# 59419 and \#59416). To generate TBK1 rescue lines, TBK1 cDNA was cloned into pDONR223 and transferred into the pHAGE-N'-FLAG-HA-IRES-puro or pHAGE-C'-FLAG-HA-IRES-puro vectors using l recombinase *in vitro* (Invitrogen). A stop codon inserted at the end of the TBK1 cDNA ensured it was untagged. The FRB-BFP-Fis1 and FKBP-GFP-TBK1 construct cloning was described previously ([@R52]) and given as kind gifts from RJY. Stably expressing FRB-BFP-Fis1 cells were sorted via flow cytometry for low BFP expression and evaluated to ensure normal mitochondrial morphology. All constructs were confirmed by DNA sequencing.

### Retrovirus or Lentiviral Generation {#S24}

Retroviral/lentiviral helpers and retroviral/lentiviral constructs were transfected into HEK293T with Lipofectamine LTX at a 1:3 ratio. 24 hr after transfection, media was changed. Infectious media containing live virus was collected 40 hr later and filtered using a 0.45 μM PES membrane. Virus was used to transduce cells with the addition 8 μg/ml of polybrene (Sigma).

### Subcloning {#S25}

TBK1 KO clone 2 was selected to stably reconstitute wild-type TBK1 to generate the rescue line. After lentiviral infection, positive cells resistant to 1 μg/mL puromycin were subcloned from single cell colonies.

### Growth Curves {#S26}

Cell growth was determined by manual cell counting and CellTiter-Glo® Luminescent Cell Viability Assay (Promega). For manual counting, 5 × 10^3^ cells were plated in a 12- well dish or 3 × 10^4^ cells were plated in a 6-well dish and counted every 24 hr period using an automated cell counter (Logos Biosystems). For luminescence experiments, 300 to 600 cells were plated in white-coated 96-well plates and read with a luminescence reader (Victor) according to the manufacturer's directions every 24 hr. Cells treated with 1 μm BX-795 were plated in the presence of the inhibitor, and the drug was replaced every 48 h.

### BrdU Analysis {#S27}

Cells were incubated with 10 μM BrdU (Sigma) for 1 hr 30 min. Cells were immediately fixed with 4% PFA and incubated with 2N HCl to denature DNA to facilitate antibody penetration. 0.1mM sodium borate buffer was used to neutralize HCl prior to routine ICC. Cells were imaged on a Zeiss LSM 510 confocal. 5 random fields of view were taken for each individual experiment to sample 200--300 cells.

### Immunocytochemistry {#S28}

Cells for imaging were plated in Nunc two-well chamber slides (Thermo Fisher). Cells were fixed with 4% PFA and permeabilized with 0.15% Triton X-100 followed by blocking with 5% BSA. Primary antibodies were incubated 1hr at RT or overnight at 4°C. Antibodies used were as followed: GRP75, p-TBK1S172 (Cell Signaling), TOM20 (Santa Cruz), AIM-1/Aurora B and BrdU (BD Biosciences), α-tubulin (Sigma), and HA.11 (Covance). Secondary AlexaFluor® (Thermo Fisher) conjugated antibodies were incubated for 1 hr RT. Cells were counterstained with 300 nM of DAPI for 5 min (Thermo Fisher). Cells were imaged on a Zeiss LSM 510 confocal. 5 random fields of view were taken for each individual experiment to sample 200--300 cells. Mitotic cells were identified by chromosome condensation and verified by α-tubulin localization/morphology. p-TBK1 localization was determined by its colocalization with either DAPI or TOM20.

FRB-BFP-Fis1 cells were grown on glass coverslips and transfected 24hrs later with FKBP-GFP-TBK1 plasmid using XtremeGene9 (Roche). 24hrs after transfection, media was changed and cells were treated with rapalog for 24hrs. Cells were either stained with 1nM MitoTracker Red CMXROS (ThermoFisher) for 15 minutes and then fixed with 4% PFA or fixed and permeabilized as above. Cells were counterstained with 1nM TO-PRO-3 (ThermoFisher) for 15 minutes. Cells were imaged on a Nikon C2 confocal. 5 random fields of view were taken for each individual experiment to sample 200--300 cells. Mitotic cells were identified by chromosome condensation.

### HR and NHEJ Recombination Assay {#S29}

Cells were transfected using Lipofectamine LTX with: pCDNA mCherry-C1, pDRGFP (Addgene\#26475) or pimEJ5GFP (Addgene\#44026), and pCBA *Sce*I (Addgene\#26477), which were kind gifts from Maria Jasin or Jeremy Stark. Cells were sorted on a FACS analyzer (BD Biosciences) to determine the population of GFP positive cells normalized to mCherry-C1 expression to account for differences in transfection efficiency ([@R4]; [@R37]).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S30}
---------------------------------------

A Student's t test was used to determine statistical significance with comparisons between two groups. For comparisons between three or more groups, a one way-ANOVA with Tukey post hoc analysis was used. A chi-square test was used to determine significance for experiments comparing theoretical Mendelian genetic probabilities to experimental probabilities for *Drosophila* eclosion experiments and mouse genotyping experiments. GraphPad Prism v7 software was used. Error bars ± SD or SEM noted in legend. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

DATA AND CODE AVAILABILITY {#S31}
--------------------------

The western blot data generated during this study are available at Mendeley Data <https://doi.org/10.17632/789652xcr3.110.17632/789652xcr3.1> The pHAGE untagged TBK1 and pHAGE N-FLAG-HA TBK1 constructs generated in this study have been deposited to Addgene under Cat\# 131791 and 131792, respectively (see [Key Resource Table](#T3){ref-type="table"}). Any other raw datasets generated during this study are currently being used for future studies and to obtain grant funding, but data is available upon request.
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![CDK1, CDK2, and CDC25 Interact with and Rescue PINK1 and Parkin Thorax Indentations\
(A) Cartoon of proteins downstream of ATM and ATR that were selected in the targeted RNAi fly screen to cross with *Pink1*^*B9*^ or *park*^*25*^ flies driven under the systemic *da-G4* or *hs-G4*, respectively.\
(B) Percentage of flies with the presence or absence of thorax indentations in the *Pink1*^*B9*^ background expressing *UAS-stg*^*RNAi*^ (\#29556) under the *da-G4* driver. Two hundred to 300 flies were screened from cross.\
(C) Percentage of flies with the presence or absence of thorax indentations in the *park*^*25*^ background expressing *UAS-CDK2*^*RNAi*^ (\#36128) under the *hs-G4* driver.\
(D) Percentage of flies with the presence or absence of thorax indentations in the *Pink1*^*B9*^ background expressing *UAS-CDK2*^*RNAi*^ (\#36128) under the *da-G4* driver.\
(E) Percentage of flies with the presence or absence of thorax indentations in the *park*^*25*^ background expressing *UAS-CDK1*^*RNAi*^ (\#36117) under the *hs-G4* driver.\
(F) Percentage of flies with the presence or absence of thorax indentations in the *Pink1*^*B9*^ background expressing *UAS-CDK1*^*RNAi*^ (\#36117) (G) *UAS-CDK2*^*RNAi*^ (\#41898) and (H) *UAS-CDK2*^*RNAi*^ (\#35267) under the *da-G4* driver. (C--F) At least 200--300 flies were screened from crosses.](nihms-1543423-f0002){#F1}

![Loss of Endogenous PINK1 and Parkin Disrupts Cell Growth and Cell Cycle\
(A) Normalized change in manual cell counts for primary MEF lines.\
(B and E) Percentage of MEFs (B) and patient fibroblasts (E) positive for BrdU.\
(C and F) Percentage of MEFs (C) and patient fibroblasts (F) with Aurora B accumulated in the nucleus.\
(D) Normalized luminescence measurements for primary patient cell lines.\
In (A) and (D), error bars indicate ±SD; n = 2 independent experiments. In (B), (C), (E), and (F), error bars indicate ±SD; n = 3 independent experiments.](nihms-1543423-f0003){#F2}

![TBK1 Is Activated During and Necessary for Mitosis\
(A) Confocal images of YFP-Parkin-expressing (green) HeLa cells demonstrating p-TBK1 (orange) localization throughout the different stages of mitosis. Cells were counterstained with DAPI (blue) and α-tubulin (red). Scale bar, 10 μM.\
(B and C) Western blot analysis of HeLa cells either in asynchronized growth (B) or synchronized at G2/M with nocodazole and released into normal growth media\
(C). β-actin was used as a loading control.\
(D and E) Normalized luminescence measurements for HeLa cells or (D) treated with 1 μM BX-795 (E) or two independent TBK1-KO clones. Error bars indicate ±SD for technical replicates.\
(F) Western blot analysis of TBK1-KO clones. β-actin was used as a loading control.\
(G) Mitotic cell counts from an asynchronous population of wild-type or TBK1-KO clones. Error bars indicate ±SD; n = 3 independent experiments.\
(H) Normalized luminescence measurements for HeLa cells, TBK1-KO clone 2, or TBK1 rescue line. Error bars indicate ±SD for technical replicates.\
(I) Western blot analysis of HeLa cells and TBK1 rescue line in asynchronous and G2/M synchronization conditions. β-actin was used as a loading control.\
(J) Confocal images of HeLa cells or TBK1-KO cells in asynchronous conditions. DAPI (blue) was used as a nuclear counterstain, and the cytoskeleton was identified by alpha-tubulin staining (red). Scale bar, 20 μm.](nihms-1543423-f0004){#F3}

![Activated TBK1 Is Sequestered from the Centrosomes to Damaged Mitochondria\
(A) Confocal images of YFP-Parkin-expressing (green) or wild-type HeLa cells detecting p-TBK1 (red) localization after double thymidine block (DTB) in DMEM or OA-treated media. Cells were counterstained with DAPI (blue) and α-tubulin (gray). White squares point to cells magnified in insets. Bottom: timeline of double thymidine synchronization for G2/M. Scale bar, 10 μM.\
(B) Percentage of cells with p-TBK1 localization at centrosome or mitochondria from conditions in (A) after DTB.\
(C and D) Percentage of mitotic YFP-Parkin or wild-type cells after DTB release into (C) OA media or (D) normal growth media.\
(E) Western blot analysis of HeLa, YFP-Parkin, or PINK1-KO cells either in asynchronous growth or synchronized in G2/M. β-actin was used as a control.\
(F) Cartoon of induced dimerization system used to physically tether TBK1 to undamaged mitochondria upon exposure to rapalog. Illustration made in BioRender ([biorender.com](https://biorender.com), with the standard academic license (G) Confocal images of FKBP-GFP-TBK1 (green) in the FRB-BFP-Fis1 (blue) parental cell line in the TBK1-KO background treated with rapalog for 24 h. Cells were counterstained with MitoTracker Red CMXRos (red). Scale bar, 10 μM. Inset scale bar, 2 μM.\
(H) Mitotic cell counts from an asynchronous population of cells expressing FKBP-GFP-TBK1 and FRB-BFP-Fis1 in the TBK1-KO background treated with or without rapalog for 24 h.\
In (B)--(D) and (H), error bars indicate ±SEM; n = 3 independent experiments.).](nihms-1543423-f0005){#F4}

![*Drosophila* Ortholog ik2 Genetically Interacts with PINK1 and Parkin\
(A) Percentage of flies with the presence or absence of thorax indentations in the *ik2\[1\]/CyO; park*^*25*^*/TM6B* self-cross. At least 200--300 flies were screened from crosses.\
(B) Percentage of flies with the presence or absence of thorax indentations from the *FM7/y; ik2/CyO* × *Pink1*^*B9*^*/Fm7c; pin/Cyo*. At least 200--300 flies were screened from crosses.](nihms-1543423-f0006){#F5}

###### 

PINK1 and Parkin Genetically Interact with DNA Damage Cell Cycle Checkpoint Proteins in Mouse

  ATM Genotype                                                        Parkin Genotype   Actual Number of Mice   Actual Frequency (%)   Expected Frequency (%)
  ------------------------------------------------------------------- ----------------- ----------------------- ---------------------- ------------------------
  Survival of Mice from the ATM+/−Parkin+/− Cross                                                                                      
  +/+                                                                 +/+               11                      6.70                   6.25
  +/+                                                                 +/−               8                       4.87                   6.25
  +/+                                                                 −/−               7                       4.27                   6.25
  +/−                                                                 +/+               22                      13.41                  12.5
  +/−                                                                 +/−               55                      33.54                  25
  +/−                                                                 −/−               29                      29.87                  12.5
  −/−                                                                 +/+               4                       2.43                   6.25
  −/−                                                                 +/−               8                       4.87                   6.25
  −/−                                                                 −/−               0                       0                      6.25\*\*\*\*
  Survival of Mice from the ATM+/−Parkin+/− × ATM+/−Parkin KO Cross                                                                    
  +/+                                                                 +/+               4                       2.79                   12.5
  +/+                                                                 +/−               7                       4.89                   12.5
  +/−                                                                 −/−               58                      40.56                  25
  +/−                                                                 +/+               68                      47.55                  25
  −/−                                                                 +/−               5                       3.49                   12.5
  −/−                                                                 −/−               1                       .07                    12.5\*\*\*\*
  Survival of Mice from the ATM+/− Cross                                                                                               
  ATM genotype                                                                                                                         
  +/+                                                                                   10                      27.03                  25
  +/−                                                                                   20                      54.05                  50
  −/−                                                                                   7                       18.92                  25

Table showing the breeding crosses and genotyped progeny from ATM+/−Parkin+/− (top) and ATM+/−Parkin+/− × ATM+/−Parkin KO mice (middle) cross. The progeny from ATM+/− crosses were also examined (bottom). ATM+/−Parkin+/− cross, \*\*\*\*p \< 0.0001; ATM+/−Parkin+/− × ATM ± Parkin KO cross, \*\*\*\*p \< 0.0001. ATM+/− cross, not significant.

###### 

PINK1 and Parkin Genetically Interact with DNA Damage Cell Cycle Checkpoint Proteins in Fly

  Genotype                                    Eclosion (%)
  ------------------------------------------- ---------------------------------------------
  *park*^*25*^                                100%
  *park*^*25*^*, ATM*^*3/+*^                  100%
  *park*^*25*^*, ATM*^*6/+*^                  100%
  *park*^*25*^*, ATM*^*8/+*^                  100%
  *ATM*^*3/6*^                                29%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *ATM*^*3/8*^                                100%
  *ATM*^*6/8*^                                72%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *park*^*25*^*, ATM*^*3/6*^                  1.5%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *park*^*25*^*, ATM*^*3/s*^                  35.9%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *park*^*25*^*, ATM*^*6/8*^                  65.4%[\*\*\*](#TFN3){ref-type="table-fn"}
  *Pink1*^*B9*^                               100%
  *Pink1*^*B9*^*;;ATM*^*6/+*^                 88.2%
  *Pink1*^*B9*^*;;ATM*^*8/+*^                 54.2%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Pink1*^*B9*^*;;ATM*^*6/8*^                 34%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Mei-41*^*\[D12\];;*^*park*^*25/+*^         100%
  *Mei-41*^*\[D12\]/+*^*;;park*^*25/+*^       100%
  *Mei-41*^*\[D12\]/+*^*;;park*^*25*^         60.5%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Mei-41*^*\[D12\]*^*;;park*^*25*^           46.6%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *hs-G4; park*^*25/+*^                       100%
  *hs-G4; park*^*25*^                         100%
  *hs-G4 \> stg-HA; park*^*25/+*^             100%
  *hs-G4 \> stg-HA; park*^*25*^               52.5%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *hs-G4; park*^*25/+*^                       100%
  *hs-G4; park*^*25*^                         100%
  *hs-G4 \> stg*^*mKEN.md*^*; park*^*25/+*^   100%
  *hs-G4 \> stg*^*mKEN.md*^*; park*^*25*^     44.5%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Ik2\[1\]/CyO*                              100%
  *Ik2\[1\]/ Ik2\[1\]*                        3.55%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Ik2\[1 / Ik2\[1\]; park*^*25/+*^           44%[\*\*\*\*](#TFN4){ref-type="table-fn"}
  *Ik2\[1\]/ Ik2\[1\]; park*^*25*^            66.15[\*\*\*\*](#TFN4){ref-type="table-fn"}

Table summarizing the ATM mutant flies used in this study. Percentage of flies eclosed for each genotype from *park*^*25*^ self-crosses; *ATM*^*3*^*/TM3* × *ATM*^*6*^*/TM3*; *ATM*^*3*^*/TM3* × *ATM*^*6*^, *park*^*25*^*/TM3*; *ATM*^*3*^, *park*^*25*^*/TM3* × *ATM*^*6*^, *park*^*25*^*/TM3*; *ATM*^*8*^*/TM3* × *ATM*^*3*^*/TM3*; *ATM*^*8*^, *park*^*25*^*/TM3* × *ATM*^*3*^, *park*^*25*^*/TM3*; *ATM*^*8*^, *park*^*25*^*/TM3* × *ATM*^*3/*^*TM3; ATM*^*8*^, *park*^*25*^*/TM3* × *ATM*^*6/*^*TM3; ATM*^*8*^*/TM3* × *ATM*^*6*^*/TM3*, and A*TM*^*8*^, *park*^*25*^*/TM3* × *ATM*^*6*^, *park*^*25*^*/TM3*. Percentage of flies eclosed from each genotype from *FM7* × *Pink1*^*B9*^*/FM7* self-crosses, *Pink1*^*B9*^*/FM7* × *ATM*^*6*^*/TM3*, *Pink1*^*B9*^*/FM7* × *ATM*^*8*^*/TM3*, and *Pink1*^*B9*^*/FM7; ATM*^*6*^*/TM3* × *Pink1*^*B9*^*/FM7; ATM*^*8*^*/TM3b*. Percentage of flies eclosed for each genotype from *Mei-41*^*\[D-12\]*^*/FM7; park*^*25*^*/TM3* self-cross. Percentage of flies eclosed for each genotype from *UAS-stg-HA*/*CyO*; *park*^*25*^*/TM3* × *hs-G4/CyO; park*^*25*^*/TM3* and *UAS-HA-stg*^*mKEN.md*^*/CyO; park*^*25*^*/TM3* × *hs-G4/CyO; park*^*25*^*/TM3*. Percentage of flies eclosed for each genotype from *ik2\[1\]/CyO* (\#5322) and *ik2\[1\]/CyO; park*^*25*^*/TM6B* self-crosses. At least 300 flies were screened from crosses.

p \> 0.001

p \> 0.0001.

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                    SOURCE                 IDENTIFIER
  ------------------------------------------------------ ---------------------- --------------------------------------------------------------
  Antibodies                                                                    
  rabbit anti-GRP75                                      Cell Signaling         Cat\#2816; RRID: AB_2120331
  rabbit anti-ATM S1981                                  Abcam                  Cat\#ab81292; RRID: AB_1640207
  rabbit anti-PINK1                                      Cell Signaling         Cat\#6946; RRID: AB_11179069
  rabbit anti-Histone H3 S10                             Cell Signaling         Cat\#53348; RRID: AB_2799431
  rabbit anti-Histone H3 T11                             Cell Signaling         Cat\#9764; RRID: AB_659964
  mouse anti-Parkin (PRK8)                               Santa Cruz             Cat\#sc-32282; RRID: AB_628104
  rabbit anti-GAPDH                                      Sigma                  Cat\#G9545; RRID: AB_796208
  mouse anti-actin                                       Sigma                  Cat\#A2228; RRID: AB_476697
  rabbit anti-Mfn2                                       in house (RJY)         N/A
  rabbit anti-TBK1 S172                                  Cell Signaling         Cat\#5483; RRID: AB_10693472
  rabbit anti-TBK1                                       Cell Signaling         Cat\#3504; RRID: AB_2255663
  rabbit anti-LC3                                        Cell Signaling         Cat\#3868; RRID: AB_2137707
  rabbit anti-ATM S1981                                  Cell Signaling         Cat\#13050; RRID: AB_2798100
  mouse anti-COXII                                       Abcam                  Cat\#ab110258: RRID: AB_10887758
  mouse anti-p53 (DO1)                                   Santa Cruz             Cat\#sc-126; RRID: AB_628082
  rabbit anti-ATM                                        Cell Signaling         Cat\#2873; RRID: AB_2062659
  guinea pig anti-p62                                    Cedarlane now Progen   Cat\#GP62-C; RRID: AB_2687531
  mouse anti-TIM23                                       BD Biosciences         Cat\#611222; RRID: AB_398754
  mouse anti-BrdU                                        Sigma                  Cat\#B8434; RRID: AB_476811
  rabbit anti-AIM1/Aurora B                              Sigma                  Cat\#A5102; RRID: AB_476740
  mouse anti-alpha-tubulin                               Sigma                  Cat\#T9026; RRID: AB_477593
  mouse anti-HA.11                                       Covance                Cat\#MMS-101R; RRID: AB_291262
  rabbit anti-TOM20                                      Santa Cruz             Cat\#sc-11415; RRID: AB_2207533
  mouse anti-ATM                                         Sigma                  Cat\#A1106; RRID: AB_796190
  Chemicals, Peptides, and Recombinant Proteins                                 
  MitoTracker Red CMXRos                                 Thermo Fisher          Cat\#M7512
  TO-PRO-3 Iodide                                        Thermo Fisher          Cat\#T3605
  Lipofectamine LTX with Plus Reagent                    Thermo Fisher          Cat\#A12621
  XtremeGENE 9 DNA Transfection Reagent                  Roche                  Cat\#XTG9-RO
  NuPAGE LDS Sample Buffer (4X)                          Invitrogen             Cat\#NP0007
  Oligomycin                                             EMD Millipore          Cat\#495455
  Antimycin A                                            Sigma                  Cat\#A8674
  Etoposide                                              Sigma                  Cat\#E1383
  BX-795                                                 Sigma                  Cat\#204001
  Thymidine                                              Sigma                  Cat\#T1895
  Nocodazole                                             Sigma                  Cat\#487928
  QVD-Oph                                                Abcam                  Cat\#ab141421
  A/C Heterodimerizer (rapalog)                          Takara                 Cat\#635056
  DL-Dithiothreitol                                      Sigma                  Cat\#D0632
  SuperSignal West Femto Maximum Sensitivity Substrate   Thermo Fisher          Cat\#34095
  ECL Prime Western Blotting System                      GE Healthcare          Cat\#RPN2232
  NEBuilder HiFi DNA Assembly Master Mix                 New England Biolabs    Cat\#E2621
  Gateway LR Clonase II Enzyme mix                       Invitrogen             Cat\#11791100
  Gateway BP Clonase Enzyme Mix                          Invitrogen             Cat\#11789013
  Puromycin                                              InvivoGen              Cat\#ant-pr-1
  Polybrene                                              Sigma                  Cat\# TR-1003-G
  Critical Commercial Assays                                                    
  CellTiter-Glo® Luminescent Cell Viability Assay        Promega                Cat\#G7570
  Deposited Data                                                                
  pHAGE-N-FLAG-HA-TBK1                                   Addgene                Cat\#131791
  pHAGE-TBK1-C-FLAG-HA (untagged)                        Addgene                Cat\#131792
  Western blot data                                      Mendeley Data          <https://doi.org/10.17632/789652xcr3.110.17632/789652xcr3.1>
  Experimental Models: Cell Lines                                               
  HeLa                                                   ATCC®                  Cat\#CCL-2; subcloned from RJY
  HCT116                                                 ATCC®                  Cat\#CCL-247
  Patient Fibroblasts                                    Coriell                GM05294
  Patient Fibroblasts                                    Coriell                GM02052
  Patient Fibroblasts                                    NINDS depository       ND40066
  Patient Fibroblasts                                    NINDS depository       ND36091
  Patient Fibroblasts                                    NINDS depository       ND34769
  HEK293T                                                ATCC®                  Cat\#CRL-3216
  ATM KO HCT116                                          This paper             N/A
  PINK1 KO HCT116                                        This paper             N/A
  Parkin KO HCT116                                       This paper             N/A
  TBK1 KO HeLa Clone 2                                   This paper             N/A
  TBK1 KO HeLa Clone 4                                   This paper             N/A
  PINK1 KO HeLa                                          [@R17]                 N/A
  TBK1 KO Clone 2 rescued with TBK1 WT HeLa              This paper             N/A
  FRB-BFP-Fis1 HeLa                                      This paper             N/A
  Experimental Models: Organisms/Strains                                        
  ATM KO                                                 Jackson Laboratories   B6.129S6-*Atm*^*tm1Awb*^/J
  Parkin KO                                              Jackson Laboratories   B6.129S4-*Prkn*^*tm1Shn*^/J
  Recombinant DNA                                                               
  hCas9                                                  Addgene                Cat\#41815
  pSpCas9(BB)-2A-Puro (PX459)                            Addgene                Cat\#48139
  pBMN-mCherry-Parkin                                    Addgene                Cat\#59419
  pBMN-YFP-Parkin                                        Addgene                Cat\#59416
  pCBASceI                                               Addgene                Cat\#26477
  pimEJ5GFP                                              Addgene                Cat\#44026
  pDRGFP                                                 Addgene                Cat\#26475
  pmCherry-C1                                            Clonetech              Cat\#632524
  pEYFP-C1                                               Clonetech              Cat\#6005--1
  gRNA Cloning Vector                                    Addgene                Cat\#41824
  pDONR223                                               Invitrogen             No longer available
  pHAGE-FRB-BFP-Fis1                                     [@R52]                 N/A
  pHAGE-FKBP-mEGFP-TBK1                                  [@R52]                 N/A

###### Highlights

-   PINK1 and Parkin genetically interact with cell cycle-regulatory proteins

-   PINK1 and Parkin do not directly signal with the nuclear DNA damage response

-   Active TBK1 sequestered at damaged mitochondria during mitophagy perturbs mitosis

-   Fly ortholog of TBK1 rescues PINK1- and Parkin-knockout phenotypes
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